Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9755)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 7, 2023 (publication date) through Dec 13, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm |
| Number | Citing Articles |
| 1 |
Larisse Longo, Gabriel Guerreiro, Luiza Behrens, Matheus Pereira, Carlos Pinzon, Carlos Cerski, Carolina Uribe‑Cruz, Mário Álvares‑da‑Silva. Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model. Biomedical Reports 2024; 22(1) doi: 10.3892/br.2024.1882
|
| 2 |
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Therapeutics and Clinical Risk Management 2023; : 839 doi: 10.2147/TCRM.S425292
|
| 3 |
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Posicionamiento sobre manejo perioperatorio y riesgo quirúrgico en el paciente con cirrosis. Revista de Gastroenterología de México 2024; 89(3): 418 doi: 10.1016/j.rgmx.2024.05.001
|
| 4 |
Yong He, Lu Chai, Han Chen, Xing-Shun Qi. Effect of different infusion approaches on safety and efficacy of terlipressin: Current controversies. World Chinese Journal of Digestology 2023; 31(17): 705 doi: 10.11569/wcjd.v31.i17.705
|
| 5 |
Christos Siafarikas, Chris J. Kapelios, Margarita Papatheodoridi, John Vlachogiannakos, Nikolaos Tentolouris, George Papatheodoridis. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use. Liver International 2024; 44(4): 884 doi: 10.1111/liv.15851
|
| 6 |
V. V. Tsukanov, A. V. Vasyutin, J. L. Tonkikh. Modern aspects of management of patients with metabolic dysfunction-associated steatotic liver disease. Meditsinskiy sovet = Medical Council 2025; (15): 96 doi: 10.21518/ms2025-342
|
| 7 |
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Position paper on perioperative management and surgical risk in the patient with cirrhosis. Revista de Gastroenterología de México (English Edition) 2024; 89(3): 418 doi: 10.1016/j.rgmxen.2024.05.001
|
| 8 |
Maxine W. Stachel, Eugene C. DePasquale. Optimizing cardiac status in the preliver transplant candidate. Current Opinion in Organ Transplantation 2024; 29(1): 50 doi: 10.1097/MOT.0000000000001119
|
| 9 |
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178: 117283 doi: 10.1016/j.biopha.2024.117283
|
| 10 |
Càndid Villanueva, Dhiraj Tripathi, Jaume Bosch. Preventing the progression of cirrhosis to decompensation and death. Nature Reviews Gastroenterology & Hepatology 2025; doi: 10.1038/s41575-024-01031-x
|
| 11 |
Xiangfeng Zeng, Sheiladevi Sukumaran. Research progress on the relationship between intestinal flora and liver cirrhosis. International Conference on Modern Medicine and Global Health (ICMMGH 2023) 2023; : 87 doi: 10.1117/12.2692644
|
| 12 |
Xue Li, Shi Liu, Jin Li, Ning Liu, Hui Li, An Ge, Liang Wang, Xie Dong, Hui Wang, Ju Liu, Lin Zhang, Hao Dong Zhang, Wei Gou. Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension. International Journal of General Medicine 2024; : 1493 doi: 10.2147/IJGM.S453107
|
| 13 |
Camille A. Kezer, Annalisa Berzigotti, Brett E. Fortune, Douglas A. Simonetto. Drug treatments to prevent first decompensation in cirrhosis. Hepatology 2024; doi: 10.1097/HEP.0000000000001117
|
| 14 |
Jun Zeng, Debesh Jha, Ertugrul Aktas, Elif Keles, Alpay Medetalibeyoglu, Matthew Antalek, Federica Proietto Salanitri, Amir A. Borhani, Daniela P. Ladner, Gorkem Durak, Ulas Bagci. Liver Cirrhosis Stage Estimation from MRI With Deep Learning. 2025 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2025; : 1 doi: 10.1109/EMBC58623.2025.11254659
|